1. European Medicines Agency. Refusal of the marketing authorisation for Aduhelm (aducanumab). 2021. https://www.ema.europa.eu/en/documents/smop-initial/refusal-marketing-authorisation-aduhelm-aducanumab_en.pdf
2. US FDA. Drugs@FDA: FDA-approved drugs. Aduhelm. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178
3. FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm
4. Three FDA advisory panel members resign over approval of Alzheimer’s drug
5. Krudys KM. November 6, 2020 BLA 761178: peripheral and central nervous system drugs advisory committee meeting. Script for FDA presentation: aducanumab for the treatment of Alzheimer’s disease: clinical overview of efficacy. https://www.fda.gov/media/143505/download